Search - tctmd.com

Displaying 21 - 40 of 107

Sort: Relevancy | Date

Presentation AHA 2023

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

Presenter: Jing Li

November 16, 2023

Presentation AHA 2023

Dapagliflozin in myocardial infarction without diabetes or heart failure

Presenter: Stefan James

November 14, 2023

News Conference News AHA 2023

New CVD Risk Tool Can Spur Even Earlier Talk About Prevention

Yael L. Maxwell

November 14, 2023

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

Todd Neale

November 13, 2023

News Conference News AHA 2023

Slash Dietary Sodium, Slash Blood Pressure: CARDIA-SSBP

Michael O'Riordan

November 12, 2023

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

Todd Neale

November 11, 2023

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

Todd Neale

November 06, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

RAPCO: Radial Artery Beats of Both RITA and Vein Grafting at 15 Years

News Conference News AHA 2022

RAPCO: Radial Artery Beats Both RITA and Vein Grafting at 15 Years

Yael L. Maxwell

November 06, 2022

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Conference News AHA 2022

Atrial Fibrosis Mediated by Gum Disease May Be Missing AF Link

L.A. McKeown

November 01, 2022

News Conference News AHA 2021

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Michael O'Riordan

November 22, 2021

News Conference News AHA 2021

Dietary Patterns, Social Pressures: AHA Offers New Nutrition Advice

Caitlin E. Cox

November 19, 2021

News Conference News AHA 2021

Aspirin Fails to Prevent Onset of Dementia in Diabetic Patients: ASCEND

Michael O'Riordan

November 17, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Shelley Wood

November 14, 2021

News Conference News AHA 2021

Small CRAVE Trial Reassures on Caffeine Safety in Rhythm Disorders

L.A. McKeown

November 14, 2021

Advertisement

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

Dapagliflozin in myocardial infarction without diabetes or heart failure

New CVD Risk Tool Can Spur Even Earlier Talk About Prevention

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

Slash Dietary Sodium, Slash Blood Pressure: CARDIA-SSBP

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

RAPCO: Radial Artery Beats Both RITA and Vein Grafting at 15 Years

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Atrial Fibrosis Mediated by Gum Disease May Be Missing AF Link

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Dietary Patterns, Social Pressures: AHA Offers New Nutrition Advice

Aspirin Fails to Prevent Onset of Dementia in Diabetic Patients: ASCEND

Canagliflozin Improves Quality of Life in HF Patients

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Small CRAVE Trial Reassures on Caffeine Safety in Rhythm Disorders

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content